11-5226778-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000518.5(HBB):c.114G>A(p.Trp38*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000131 in 152,254 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000518.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152136Hom.: 0 Cov.: 32
GnomAD4 exome Cov.: 36
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152254Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74440
ClinVar
Submissions by phenotype
not provided Pathogenic:4
The HBB c.114G>A (p.Trp38*) variant (also known as Codon 37 (G>A) and W37X) causes the premature termination of beta-globin (HBB) protein synthesis and is associated with beta(0)-thalassemia (PMID: 3006832 (1986), 15008262 (2004), 18096416 (2008), 23321370 (2013), 23510507 (2013)). -
The HBB c.114G>A; p.Trp38Ter variant (rs33974936, HbVar ID: 841), also known as Codon 37 (G->A), is reported in multiple individuals diagnosed with beta-thalassemia, and associated with beta-0 trait (Asadov 2013, Boehm 1986, Fernandes 2011, Gallano 1992, HbVar database and references therein). This variant is also reported in ClinVar (Variation ID: 15405) and is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Asadov C et al. Identification of two rare Beta-globin gene mutations in a patient with Beta-thalassemia intermedia from Azerbaijan. Hemoglobin. 2013; 37(3):291-6. PMID: 23510507. Boehm C et al. Use of oligonucleotide hybridization in the characterization of a beta zero-thalassemia gene (beta 37 TGG----TGA) in a Saudi Arabian family. Blood. 1986; 67(4):1185-8. PMID: 3006832. Fernandes A et al. Molecular analysis of B-thalassemia patients: first identification of mutations HBB:c.93-2A>G and HBB:c.114G>A in Brazil. Hemoglobin. 2011; 35(4):358-66. PMID: 21797703. Gallano P et al. High prevalence of the beta-thalassaemia nonsense 37 mutation in Catalonians from the Ebro delta. Br J Haematol. 1992; 81(1):126-7. PMID: 1520612. -
For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Trp38*) in the HBB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HBB are known to be pathogenic (PMID: 23637309). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with beta thalassemia (PMID: 3006832, 28670940). ClinVar contains an entry for this variant (Variation ID: 15405). -
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Reported as pathogenic in a well-curated hemoglobin database but additional evidence is not available (Giardine et al., 2014); Not observed at significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 27535533, 22385009, 3006832, 23510507, 21797703) -
beta Thalassemia Pathogenic:3
- -
- -
- -
Beta zero thalassemia Pathogenic:1
- -
Hemoglobinopathy Pathogenic:1
Variant summary: The HBB c.114G>A (p.Trp38X) variant results in a premature termination codon, predicted to cause a truncated or absent HBB protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. c.118C>T/p.Gln40X, c.130G>T/p.Glu44X, etc). One in silico tool predicts a damaging outcome for this variant. This variant is absent in 30964 control chromosomes. It has been reported in many BTHAL patients (both intermediate and major types) in both homozygous and comound heterozygous status. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic/ likely pathogenic. Ithanet lists variant as ' Globin gene causative mutation' with relative frequencies of 6.3% in Jordan, 4.05% in Syria, 1.08% in Tunisia, 1% in Egypt, 0.3% in Czech Republic, 0.3% in Slovakia, 0.3% in Pakistan, and 0.3% in Spain. Taken together, this variant is classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at